---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071249"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:38:15.098574+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics shareholders approve officer liability limitation amendment and elect director

## Summary
- Stockholders approved Certificate of Amendment to limit officer liability as permitted by Delaware law.
- Gina Chapman elected as Class III director with 19,701,297 votes for, 101,960 withheld, 2,418,006 broker non-votes.
- Ernst & Young LLP ratified as independent auditor for FY 2024 (22,210,935 for, 2,174 against, 8,154 abstain).
- Certificate of Amendment filed with Delaware Secretary of State, effective June 13, 2024.

## SEC filing metadata
- accession: 0001104659-24-071249
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465924071249/0001104659-24-071249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465924071249/tm2417220d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071249
- JSON: https://secwatch.observer/filing/0001104659-24-071249.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.